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Idiosyncratic drug-induced liver injury (iDILI) is a serious concern in drug development. The rarity and
multifactorial nature of iDILI makes it difﬁcult to predict and explain. Recently, human leukocyte antigen
(HLA) allele associations have provided strong support for a role of an adaptive immune response in the
pathogenesis of many iDILI cases; however, it is likely that an adaptive immune attack requires several
preceding events. Quantitative systems pharmacology (QSP), an in silico modeling technique that le-
verages known physiology and the results of in vitro experiments in order to make predictions about how
drugs affect biological processes, is proposed as a potentially useful tool for predicting and explaining
critical events that likely precede immune-mediated iDILI, as well as the immune attack itself. DILIsym, a
QSP platform for drug-induced liver injury, has demonstrated success in predicting the presence of
delayed hepatocellular stress events that likely precede the iDILI cascade, and has successfully predicted
hepatocellular stress likely underlying iDILI attributed to troglitazone and tolvaptan. The incorporation of
a model of the adaptive immune system into DILIsym would represent and important advance. In
summary, QSP methods can play a key role in the future prediction and understanding of both immune-
mediated and non-immune-mediated iDILI.
© 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug-induced liver injury (DILI) is remains a key problem in
drug development [1]. Of special concern is idiosyncratic DILI
(iDILI), which has begun to be identiﬁed as separate from direct (or
“intrinsic”) DILI. In contrast to intrinsic DILI, in which a clear toxic
doseeresponse could be induced by the drug in a majority of the
population (e.g. acetaminophen), idiosyncratic DILI (iDILI) is char-
acterized by a complex doseeresponse relationship with only a
small minority of the population susceptible to the toxicity [2].
A well-known and studied example of a drug with an iDILI lia-
bility is troglitazone. In clinical trials, troglitazone showed generally
minor elevations in serum alanine aminotransferases in only a
small subset of the population (<2%) [3] and the ability of the drug
to cause progressive liver injury was not appreciated; it was
therefore approved for diabetes treatment in 1997. While on thedhead).
y of Xenobiotics. Published by Elmarket, however, a small number of patients developed severe liver
injury after several months of troglitazone treatment, resulting in
liver transplant or death; troglitazone was subsequently removed
from the market [4,5]. Examples of other drugs associated with
iDILI reactions include ﬂucloxacillin, ximelagatran, and lapatinib
[6e8].
The preponderance of data support a role for the adaptive im-
mune system in iDILI caused by many and perhaps most drugs. The
implication of adaptive immune responses, particularly T cell re-
sponses, in iDILI has historically rested largely on phenotypic
characteristics of the injury. Particularly, liver injury is character-
istically delayed, as would be expected in the development of an
antigen-speciﬁc T cell response, and injury is generally manifested
rapidly on re-challenge, as one might expect for a memory T cell
response. This phenotypic evidence has been strongly bolstered by
relatively recent data showing HLA associations for liver injury
caused by particular drugs, including amoxicillin-clavulanate,
ximelagatran, and lapatinib, among others [9]. Because HLA al-
leles encode major histocompatibility class I or class II proteins that
bind and present peptide antigens to CD8þ or CD4þ T cells,sevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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observed injury. More direct evidence of T cell responsiveness has
emerged recently through in vitro culture of T cells from HLA-typed
donors exposed to drugs of interest. Amoxicillin-clavulanate and
ﬂucloxacillin-speciﬁc T cell lines and clones have been generated
and characterized, shedding light on antigen presentation and Tcell
effector functions [10e12]. Despite these data, there remain many
unknowns on the exact nature of T cell mediated DILI, including
which subsets of T cells are involved, where the T cells are primed,
what the role of regulatory cells might be, and why the majority of
individuals, even those carrying the knownHLA risk alleles, will not
suffer injury.2. Conceptual framework for T cell-mediated iDILI
It is likely that a series of necessary but not sufﬁcient steps
precede the adaptive immune response that is thought to be a
characteristic of idiosyncratic DILI. This is based on the prevailing
concept that a robust adaptive immune response requires “danger
signals” elicited from the target tissues that result from activation
of innate immune cells in that tissue [13]. It is therefore likely that
the necessary initial steps in a drug-mediated adaptive immune
attack on the liver include generation of hepatocyte stress, creation
of neoantigens, release of damage associated molecular patterns
(DAMPs) and activation of innate immune cells in the liver. Fig. 1
shows a schematic of this proposed iDILI cascade. Reactive
metabolite formation has been identiﬁed as a potential instigator of
the iDILI cascade [14], though it is unclear whether the reactive
metabolite is involved in generation of neoantigens, hepatocyte
stress, or both processes. Other mechanisms of generating cellular
stress, such as bile acid accumulation or mitochondrial toxicity,
could also help trigger the idiosyncratic immune response.
Prediction of the precipitating events, for example character-
ization of hepatocellular stress and resulting innate immune re-
sponses, can be accomplished through the use of quantitative
systems pharmacology (QSP) modeling. QSP modeling is a com-
puter modeling technique that incorporates known biology and
physiology in order to better understand in vitro data. By placing
those data in the proper biological context, QSP models seek to
provide better predictions of how a biological system would react
to a given stimulus [15]. QSP modeling is common in research on
drug efﬁcacy, but recently it has been adopted as a tool for explo-
ration of potential drug toxicity.3. QSP models as gateways to iDILI
Strong evidence to support the proposed initiating events for
iDILI has come from studies that have utilized DILIsym®, a QSP
platform model of DILI that harnesses the physiology of the liver inFig. 1. Schematic of the steps involved in the proposed framework for the initiation of
adaptive immune-mediated idiosyncratic DILI responses.order to translate in vitro toxicity data to predictions of a drug's
potential to cause DILI. DILIsym has been developed by the DILI-sim
Initiative, a pre-competitive consortium of pharmaceutical com-
panies with the mandate to create a software tool that can predict
DILI during clinical drug development (http://www.dilisym.com/).
The DILIsym software contains a PBPK sub-model that describes
drug distribution into the liver as well as several sub-models that
describe physiological processes occurring within the liver. Among
these sub-models are bile acid homeostasis and disruption; mito-
chondrial activity and toxicity; reactive metabolite generation and
disposition; oxidative stress; inﬂammation mediated by the innate
immune system; and the overall hepatocyte life cycle.
Other QSP approaches to predicting DILI have tended to focus on
the case of acetaminophen. Recent work has been done in con-
structing an agent-based model of the liver that represents acet-
aminophen toxicity; this model also represents some inter-
individual variability in response that could aid in prediction of
rare hepatotoxicity [16]. Other approaches have used QSPmodeling
to predict the likelihood that an acetaminophen overdose would
progress to liver failure based on a patient's aminotransferase levels
and plasma acetaminophen concentration at the time of presen-
tation [17]. These approaches may improve management of acet-
aminophen hepatotoxicity, which constitutes a considerable
proportion of DILI cases. The approach to improve prediction of
patient outcomes based on measurable biomarkers is potentially
extensible to other compounds but may require distinct QSP
models. Further, the lack of mechanistic representation of toxicity
within the cell, suggests these models may be most applicable on
clinical presentation and less suited for drug development.
A different approach that uses an intracellular mechanistic
representation to explain hepatotoxicity has also been explored.
This approach used hepatocyte-derived gene expression data to
bridge the gap between predicted exposure and predicted toxicity.
This approach successfully predicted rat and patient responses to
acute azathioprine overdose [18]. Because this model also uses a
PBPK approach, it appears well-suited to evaluate the effect of
subject characteristics (e.g., age, weight, sex) on exposure and
thereby, on response to hepatotoxins. However, it does not appear
to include response variability related to the mechanism of toxicity.
It will be informative to see this approach applied to other com-
pounds, in order to determine if a common QSP model can address
multiple pathways or if the abundance of gene expression patterns
requires a distinct QSP model for each compound. Additionally,
while the rat toxicity predictions suggest that QSP modeling can
apply gene expression proﬁles to predict liver response, the mul-
tiplicity of gene expression patterns and their nebulous relation-
ship to functional tissue changes suggests the need for additional
compound modeling.
Contrastingly, DILIsym has used the inputs generated by
mechanistic in vitro assays to explain intrinsic toxicity by several
molecules across different mechanisms of toxicity. The reactive-
metabolite mediated toxicity of methapyrilene in rats was
correctly predicted by DILIsym, and species differences were
explained as well [19]. DILIsym also predicted the species differ-
ences in the bile-acid mediated toxicity of bosentan, and properly
compared the DILI-generating bosentan to a non-DILI-risk drug,
telmisartan [20]. DILIsym also correctly predicted the difference in
toxicity between tolcapone (rare DILI risk) and entacapone (no DILI
risk), both of which are mitochondrial toxins in vitro [21]. These
examples suggest that DILIsym can predict cellular stress from
numerous mechanisms that might serve as an initiating event for
an adaptive immune attack.
DILIsym facilitates predictions of hepatotoxicity based on inputs
from mechanistic in vitro toxicity assays. The assays currently used
for DILIsym inputs include transporter vesicle assays that yield a Ki
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mitochondrial assays that detail the drug's effect on oxygen con-
sumption rate of the in vitro cell system [21,22,24]; and oxidative
stress assays that determine the drug's ability to initiate oxidative
stress in the cell [22].
DILIsym uses current knowledge about liver physiology to
construct a network of interacting modules that simulate the effect
of the drug, as assayed by the aforementioned in vitro systems, on
the liver as a whole. The basic structure of the model is shown in
Fig. 2. Liver exposure is estimated using a PBPKmodel of the drug in
question; the drug in the liver causes mitochondrial dysfunction,
bile acid accumulation, or oxidative stress; these perturbations
cause cellular stress, loss of ATP, and death by either apoptosis or
necrosis; and cell death leads to the release of biomarkers and, in
the case of necrosis, to the activation of the innate immune system.
In Fig. 1, the elements of the iDILI cascade that are currently rep-
resented in DILIsym are in the red box; this includes the initial
hepatocyte stress, the release of damage-associated molecular
patterns (DAMP), and the innate immune response.
The initiation of an adaptive immune response critically in-
volves innate immune cells. For example, dendritic cells are innate
immune cells widely considered to stand at the interface between
innate and adaptive immunity [25,26]. The dendritic cell pheno-
type (i.e., inﬂammatory vs. tolerogenic) is a function of the micro-
environment in which antigen is encountered, and dendritic cell
phenotype strongly inﬂuences the outcome of antigen presentation
on T cell activation, differentiation, and function [26,27]. As a ﬁrst
step in representing the complex set of events involved in the
initiation of an adaptive immune response, DILIsym represents
some of the innate immune cells that have been characterized in
intrinsic APAP-mediated toxicity. The innate immune representa-
tion is based largely on data from mice, which were the most
plentiful, and has been adapted to rats and humans, with species-
speciﬁc data where available. DILIsym represents the resident
macrophage population (i.e., Kupffer cells) and the liver sinusoidal
endothelial cells (LSEC) population. During APAP-induced hepato-
cyte necrosis, DAMP molecules, such as high mobility group box 1
(HMGB1), are released from dying cells. DAMPs activate immune
cells with resulting mediator production and effects on injury
progression and resolution. Liver innate immune responses have
the potential to include other cell types and functionality thanFig. 2. Overview of the interactions amondescribed in DILIsym thus far. However, this initial representation
includes a relatively complex liver microenvironment, e.g., pro-
inﬂammatory, anti-inﬂammatory, and pro-regenerative immune
regulation of hepatocytes, that is largely consistent with the
available data [28] and positions DILIsym to continue towards a
representation of adaptive immunity.
4. DILIsym ﬁndings relevant to iDILI
Recent work using DILIsym has focused on explaining the
observed toxicity of two compounds that are generally considered
as examples of iDILI: troglitazone and tolvaptan. Severe troglita-
zone hepatotoxicity is rare and presentation is typically months
after starting treatment [3]. Several mechanisms have been pro-
posed as important in explaining troglitazone's DILI liability. Chief
among these is bile acid accumulation within the hepatocyte;
in vitrowork has shown that both troglitazone and its accumulating
sulfate metabolite are powerful inhibitors of the bile salt export
pump (BSEP), which is important in maintaining the enterohepatic
recirculation of bile acids [5,23].
Mild dose-dependent elevations in serum alanine amino-
transferase (ALT) levels were observed in a small portion of the
population in the troglitazone clinical trials [3]. Using the in vitro
data on BSEP inhibition, as well as other in vitro data on the in-
hibition of basolateral bile acid transporters, DILIsym was able to
closely predict the incidence of ALT elevations in clinical trials [23].
DILIsym also correctly predicted the relative liver safety of pio-
glitazone, an in-class drug with similar BSEP inhibitory properties;
DILIsym also explained the species differences in toxicity between
humans and rats, which do not develop hepatotoxicity due to
troglitazone. Interestingly, DILIsym simulations also recapitulated
the delayed presentation of troglitazone-mediated hepatotoxicity
(i.e. peak serum ALT levels). Bile acid accumulation is a relatively
slow process; intracellular bile acid levels at least 10-fold above
the normal physiologically observed range must be reached in
order for bile acids to cause toxicity [29]. In the case of troglita-
zone, this is further compounded by the involvement of the main
BSEP-inhibiting sulfate metabolite, which accumulates over time.
The DILIsym experience with troglitazone suggests that mecha-
nisms apart from an adaptive immune attack can explain the la-
tency of the observed iDILI attack; as shown in Fig. 3, time to peakg the various sub-models of DILIsym.
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within the ﬁrst month to as late as six months after the initiation of
simulated dosing [23]. It has been shown that reactive metabolites
are produced from troglitazone in the liver and these are capable
of covalent binding to liver proteins [30], potentially created
neoantigens. However, we have been unable to ﬁnd data on tro-
glitazone DILI patients rechallenged with the drug to observe
whether there was rapid recurrence of injury, and DNA from tro-
glitazone DILI patients is not available for HLA genotyping. Since
troglitazone is no longer on the market, it may remain unclear
whether troglitazone liver injury involved adaptive immune
mechanisms.
DILIsym has also been used to explore the mechanistic un-
derpinnings of observed hepatotoxicity due to tolvaptan. While
tolvaptan is safe when used as a treatment for hyponatremia in
heart failure or in Syndrome of Inappropriate Antidiuretic Hor-
mone (SIADH), ALT elevations and Hy's Law cases have been
observed in clinical trials for autosomal-dominant polycystic kid-
ney disease (ADPKD) [31]. While individuals with ADPKD are often
treated with a higher dose of tolvaptan than individuals with
hyponatremia or CHF, the relationship between dose and ALT ele-
vations is unclear. The combination of a delayed presentation and
frequently immediate recurrence of toxicity following rechallenge
have led to a proposed role for the adaptive immune system in
tolvaptan-mediated DILI [31]. However, in vitro experiments have
suggested that tolvaptan is also an inhibitor of bile acid transporters
[32] and of the mitochondrial electron transport chain; DILIsym
was used to demonstrate that these mechanisms could be
responsible for the initiating event that would subsequently trigger
the adaptive immune attack [22].
In the case of both troglitazone and tolvaptan, DILIsym pre-
dicted the delayed presentation of DILI among many of the clinical
subjects. In both cases, bile acid accumulation occurred over theFig. 3. Simulated serum ALT and viable liver mass fraction in susceptible simspace of months, and simulated ALT elevations often did not
manifest until bile acids had accumulated sufﬁciently. For tol-
vaptan, simulations suggested that disease progression may in-
crease drug exposure to the liver, contributing to the delayed
presentation as well [22]. The modeling of troglitazone and tol-
vaptan thus demonstrates that one should not consider delayed
presentation of DILI alone as certain evidence of an adaptive im-
mune attack. Indeed, there is currently little mechanistic evidence
that multiple months are required to mount an adaptive immune
response; the gradual building of hepatocyte stress to some
threshold could therefore account for much of the characteristic
latency observed in iDILI.
The DILIsym simulations for troglitazone and tolvaptan (and for
bosentan and tolcapone as well) used simulated populations
(SimPops™) that include variability in several key parameters
related to each toxic mechanism. The variability present in these
SimPops™ has led to the identiﬁcation of certain potential under-
lying risk factors for toxicity that are unrelated to HLA associations.
For example, in both cases SimPops parameters related to bile acid
accumulation were correlated with the susceptibility to ALT ele-
vations [20,23]. These parameters do not account for all the sus-
ceptibility within the population; with these and other modeled
drugs, multiple additional parameters are almost always correlated
with ALT elevations to some extent. In the case of tolvaptan, the
toxicity was multifactorial in terms of mechanism as well, with
both bile acid accumulation and mitochondrial electron transport
chain inhibition contributing to the observed hepatocellular stress
[22]. As such, system parameters relating to both bile acid pro-
cessing and mitochondrial function were correlated with ALT ele-
vations. It is often noted that most individuals carrying the
identiﬁed HLA risk alleles for a given iDILI response do not develop
IDILI while receiving the drug [7]; the series of initiating events
depicted in Fig. 1 provide an attractive hypothesis to account forulated individuals given A) 400 mg and B) 600 mg troglitazone daily.
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events themselves would only manifest in a small, susceptible
subgroup of the population and presumably only those within this
subgroup carrying an HLA risk allele would develop iDILI.
5. Inclusion of T cell-mediated liver injury in DILIsym
It is important to note that DILIsym does not predict whether an
adaptive immune attack will occurdonly whether the presence of
an initiating event causing cell stress, and thus the potential for an
adaptive immune attack, exists. There are, of course, several other
compoundsdbosentan and tolcapone among themdthat cause
rare DILI with a similar frequency to tolvaptan but that have not
been identiﬁed as potentially involving the adaptive immune sys-
tem. These compounds are currently indistinguishable in DILIsym,
which correctly predicts the toxic potential behind all three of these
compounds but does not predict that tolvaptan may be a potential
adaptive immune target while bosentan and tolcapone are not.
While QSP modeling is currently used to predict the initiating
events for iDILI, it may be the case that QSP in general could not
predict the immunogenicity of various drugs. However, even if that
is the case, QSPmodels could be used to understand the resulting T-
cell response during an adaptive immune attack (Table 1).
As such, we believe that it is appropriate to begin the process of
incorporating a QSP model of the adaptive immune system into
DILIsym. Illuminating the potential contribution of antigen-speciﬁc
T cell activity in rare event DILI is a complicated and challenging
undertaking. However, there are several arguments that support
the development of a QSP model to address this goal. Firstly, a new
animal model of DILI has been developed, in which injury appears
to be T cell mediated. The model is PD1/ mice treated with anti-
CTLA-4 monoclonal antibody and subsequently treated with drugs
known to have human DILI liabilities. With amodiaquine, there wasTable 1
Analysis of questions in DILI that would and would not be answered by current and
future QSP approaches.
DILI question Addressed by
current QSP
approaches
Addressed by
future QSP
approaches
Can toxicity mechanisms identiﬁed in vitro
explain clinically observed liver enzyme
abnormalities?
Yesa
Can a different dosing approach reduce the
frequency of clinically observed liver enzyme
abnormalities?
Yes
Can patient susceptibility factors be identiﬁed? Yes
Can on-treatment biomarkers of later liver
enzyme abnormalities be identiﬁed?
Yes
Can liver safety be compared between lead and
back-up compounds?
Yes
Can liver safety of combination therapies be
addressed?
Yes
Can QSP modeling provide additional
information to aid interpretation of clinical
liver enzyme abnormalities?
Yes
Can QSP modeling account for discrepancies
between pre-clinical and clinical liver safety?
Yes
Can clinical liver liabilities be prospectively
identiﬁed from pre-clinical data?
TBD
Can T cell mediated DILI be prospectively
identiﬁed?b
TBD
TBD ¼ to be determined.
a Toxicity mechanisms in DILIsym currently include oxidative stress, bile acid
accumulation, and mitochondrial dysfunction.
b It is likely that many of the questions addressed by current approaches can be
expanded to include T cell mediated liver injury (e.g., Can T cell mediated liver injury
explain clinically observed liver enzyme abnormalities?”). However since all T cell
applications are speculative, T cell-centric DILI questions have been aggregated to
one key question.delayed presentation of liver enzyme elevations, which was shown
to be mediated by CD8þ T cells [33]. Similar delayed presentation
was demonstrated for isoniazid and nevirapine [34]. PD1 and CTLA-
4 are inhibitory receptors that serve to inhibit T cell responses,
promoting immune tolerance. Thus, this model not only constitutes
the ﬁrst animal model of T cell mediated DILI but also holds the
promise of illuminating the role of inhibitory receptors and their
inﬂuence on reducing or preventing iDILI. Secondly, there are some
inherent advantages related to themodeling (QSP) discipline. AQSP
effort can leverage published mathematical models of T cell re-
sponses in other systems [35,36]. Published mathematical models
have often identiﬁed mathematical solutions for complex but
general biological relationships, which can inform the particular
mathematical equations needed (e.g., antigen presentation) and/or
general baseline parameter values (e.g., circulating T cell concen-
trations). A QSP effort can also leverage experimental data from
related systems. For example, use of recombinant adeno-associated
virus (rAAV) based technology to engineer hepatocyte-speciﬁc
expression of the ovalbumin (OVA) antigen in mice, combined
with adoptive transfer of OVA-speciﬁc OT-1 T cells, permitted
elegant studies on the regulation of hepatocyte-targeted T cell re-
sponses [37]. Lastly, a QSP effort brings mathematical rigor to the
use of the data. The effort to mathematically describe biological
phenomena can uncover under-appreciated gaps in the available
data (e.g., absence of data on the intracellular bile acid concentra-
tion associated with hepatocyte death) or can lead to unexpected
but provocative results (e.g., drug-mediated bile acid accumulation
could be sufﬁcient to explain delayed hepatotoxicity) [20,23].
Finally, in addition to the inherent advantages of QSP, this effort
would leverage DILIsym, and its proven representation of intrinsic
toxicity, aspects of which are likely required for initiation of an
adaptive immune response. These arguments, together with the
great unmet need to understand and hopefully mitigate T cell
mediated DILI, underlie the decision to incorporate T cells re-
sponses within DILIsym focusing initially on a mouse representa-
tion, based on data availability.
The arguments to incorporate T cell responses within DILIsym
are balanced by a relative dearth of data delineating Tcell responses
in DILI, particularly in vivo. As described above, there is an intent to
leverage both drug-speciﬁc and drug-independent experimental
data sets. Multiple determinants of the T cell response will be
included and optimized to conﬁrm simulated behaviors consistent
with experimental data (e.g., greater response to amodiaquine with
blockade of PD1 and CTLA-4). Key assumptions and empirically-
derived parameter values will be documented. Predictions will be
made for the effect of key determinants on outcomes for which
experimental data have not been published (e.g., antigen-
presenting cell type on CD8þ T cell response to amodiaquine). All
of these (assumptions, non-experimentally deﬁned parameter
values, and predictions) will form the basis for proposed experi-
mental studies. Finally, an input panel will be developed, describing
experimental data sets that can be used as DILIsym inputs for in
silico investigation of putative T cell-mediated toxicity. Thus, the
representation of T cell responses within DILIsym is intended as a
tool to organize our current understanding within a unifying
framework and to identify key uncertainties for the collection of
new data to improve our understanding in the future.
In planning the inclusion of T cell mediated liver injury in DILI-
sym, one must also consider the selection of parameters and value
ranges for SimPops. As illustrated above, the simulation of interin-
dividual variability via SimPops allows the reproduction of relatively
low frequency DILI and the subsequent investigation of contributing
mechanisms. Key determinants of the T cell response as reported in
the literature (e.g., antigen level, degree of inhibition) or identiﬁed
via simulations, are likely to be included as SimPops variables.
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DILI liabilities [2] and are likely to be of great interest. Importantly,
HLA associations alone have been shown to have low predictive
value [38], and at least one study suggests that drug-speciﬁc T cell
responses can be generated in vitro with antigen-presenting cells
fromHLA-matched donors aswell as fromHLAmis-matched donors
[11]. Evenwhen HLA-restricted responses are observed in vitro [10],
the frequency of successful T cell priming in vitro is greater than one
would expect if the in vitro results were directly correlated with
in vivo DILI. It seems reasonable to hypothesize that the many reg-
ulatory mechanisms acting in vivomay account for this discrepancy.
Taken together then, HLA associationswill certainly be used to guide
the selection of compounds for which T cell mediated liver injury
appears likely; however, SimPops will initially focus on mechanistic
parameters, some of which may be related to HLA molecules, but
will not represent HLA associations per se.6. Conclusion
Incorporating a QSP model of adaptive immune responses
within the larger framework provided by DILIsym will provide
insight by consolidating available data in a common framework,
will help identify key data gaps, will lead to prospective pre-
dictions, and may guide the direction of future experimental
studies. By combining our growing knowledge on the role of the
adaptive immune system in rare DILI events, the results of in vitro
assays on potentially hepatotoxic drugs, knowledge about drug
distribution and toxicity, and the broader biological context, QSP
modeling will play a key role going forward in predicting and
preventing idiosyncratic DILI in drug development.Conﬂict of interest
Drs. Woodhead, Howell, Siler, and Shoda are employees of, and
shareholders in, DILIsym Services, Inc. Dr. Watkins is a shareholder
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